Immune responses against different variants of SARS-CoV-2 including Omicron following 6 months of administration of heterologous prime-boost COVID-19 vaccine | Zendy

Gajanan Sapkal | Zendy; Rajni Kant | Zendy; Gaurav Raj Dwivedi | Zendy; Rima R. Sahay | Zendy; Pragya D. Yadav | Zendy; Gururaj Deshpande | Zendy; Rajeev Singh | Zendy; Dimpal A. Nyayanit | Zendy; Deepak Y. Patil | Zendy; Anita Shete-Aich | Zendy; Kamran Zaman | Zendy; Anil K Chaudhari | Zendy; Nivedita Gupta | Zendy; Samiran Panda | Zendy; Priya Abraham | Zendy; Balram Bhargava | Zendy

Open Access

Immune responses against different variants of SARS-CoV-2 including Omicron following 6 months of administration of heterologous prime-boost COVID-19 vaccine

Author(s) -

Gajanan Sapkal,

Rajni Kant,

Gaurav Raj Dwivedi,

Rima R. Sahay,

Pragya D. Yadav,

Gururaj Deshpande,

Rajeev Singh,

Dimpal A. Nyayanit,

Deepak Y. Patil,

Anita Shete-Aich,

Kamran Zaman,

Anil K Chaudhari,

Nivedita Gupta,

Samiran Panda,

Priya Abraham,

Balram Bhargava

Publication year - 2022

Publication title -

journal of travel medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.985

H-Index - 59

eISSN - 1708-8305

pISSN - 1195-1982

DOI - 10.1093/jtm/taac033

Subject(s) - heterologous , medicine , virology , titer , covid-19 , vaccination , immune system , antibody , immunology , neutralizing antibody , virus , biology , disease , infectious disease (medical specialty) , gene , genetics , outbreak

Comparative analysis at 1- and 6-month post-vaccination showed modest reduction in S1-RBD IgG antibody and NAb titers against B.1, Alpha, Beta and Delta variants in heterologous and homologous vaccine recipients groups. However, significant reduction in NAb titers against Omicron in vaccinees’ sera post-6 months underlines need for cautious prospective follow-up.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research